Patients with vascular dementia who received intravenous cerebrolysin showed significantly better cognitive scores and overall functioning compared to placebo over 24 weeks.
67.5% vs 27.0%Combined response rate (improvement in both cognition and overall function) with cerebrolysin versus placebo
What the researchers found
Cerebrolysin produced statistically significant improvements on both primary endpoints in vascular dementia patients. Cognitive scores (ADAS-cog+) improved by 10.6 points in the cerebrolysin group versus 4.4 points with placebo (P<0.0001). Overall clinical functioning (CIBIC+) also showed significant improvement (P<0.0001).
Responder analyses were particularly striking: 82.1% of cerebrolysin patients achieved meaningful cognitive improvement (≥4-point ADAS-cog+ change) versus 52.2% on placebo. The combined response rate — improvement on both cognition and overall function — was 67.5% versus 27.0%. The odds ratio for achieving a favorable combined response with cerebrolysin was 5.63 (P<0.05), indicating patients were more than five times as likely to respond to treatment.
Why it matters
Vascular dementia is the second most common form of dementia after Alzheimer's disease, yet no drug has been approved by the FDA or EMA to treat it. This leaves millions of patients without effective pharmacotherapy. This trial provides some of the strongest evidence that cerebrolysin — a neurotrophic peptide preparation — can meaningfully improve cognition and daily functioning in these patients, potentially filling a critical treatment gap.
How the study worked
This was a multicenter, double-blind, placebo-controlled, randomized trial involving 242 patients meeting diagnostic criteria for vascular dementia. Patients received either intravenous cerebrolysin 20 mL or placebo once daily, administered over two treatment cycles as add-on therapy to aspirin. The primary endpoint was a combined measure of cognition (ADAS-cog+) and overall clinical functioning (CIBIC+) at 24 weeks.
What this study cannot tell us
The trial enrolled 242 patients, which is moderate but not large by modern standards. The study was conducted in European centers and may not generalize to all populations. Cerebrolysin requires daily intravenous infusions, which is a significant practical barrier compared to oral medications. The 24-week follow-up does not address whether benefits persist long-term. The manufacturer (EBEWE Pharma) was involved in the study, which could introduce bias.
How to read the evidence
This is a well-designed double-blind, randomized, placebo-controlled, multicenter trial — the gold standard for clinical evidence. The large effect sizes and highly significant P-values strengthen confidence in the findings. However, the moderate sample size (242 patients) and manufacturer involvement are considerations.
When this study was published
Published in 2011, the findings remain relevant as vascular dementia still lacks approved pharmacotherapy. Cerebrolysin continues to be used clinically in many countries and studied in ongoing trials.
The bigger picture
Cerebrolysin has been used clinically in parts of Europe and Asia for decades, primarily for stroke recovery and various forms of dementia, though it lacks FDA approval. This trial is one of the larger, better-designed studies testing it specifically in vascular dementia. The robust effect sizes reported here — combined with cerebrolysin's known neurotrophic peptide content — contribute to the broader research into whether peptide-based neurotrophic therapies can address neurodegenerative conditions that currently have few treatment options.
Questions still open
- Can cerebrolysin's benefits in vascular dementia be sustained beyond 24 weeks with continued or intermittent treatment cycles?
- Which specific neurotrophic peptides within cerebrolysin are responsible for the cognitive improvements?
- Would cerebrolysin be effective if started earlier in the disease course, before significant cognitive decline has occurred?
Common questions
What is cerebrolysin and what is it made of?
Why isn't there an approved drug for vascular dementia?
Read the original research
Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 20(4), 310-8
Citation
Guekht, Alla B; Moessler, Herbert; Novak, Philipp H; Gusev, Evgenyi I. (2011). Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 20(4), 310-8. https://doi.org/10.1016/j.jstrokecerebrovasdis.2010.01.012